Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transcription Factors in Breast Cancer Oncogenesis and Progression.

Molecular and cellular biology·2026
Same author

Assessing Quality of Colorectal Cancer Care at Commission on Cancer Accredited Hospitals.

Journal of the American College of Surgeons·2026
Same author

GNAQ Induces Melanomagenesis in Mitfa-Independent Melanocyte Progenitors in a Zebrafish Model of Uveal Melanoma.

Cancer research·2026
Same author

Multiomic analyses delineate human neuroendocrine tumor cell states in relation to normal enteroendocrine cell ontogeny.

The Journal of clinical investigation·2026
Same author

Evaluation of the National Accreditation Program for Rectal Cancer and Association with Oncologic Outcomes After Proctectomy.

Journal of the American College of Surgeons·2026
Same author

Association of Rectal Cancer Accreditation with Patient Volume and Procedural Trends in the US.

JAMA surgery·2026

Related Experiment Video

Updated: Jun 22, 2026

Identification and Protection of the Recurrent Laryngeal Nerve during Transoral Robotic Thyroidectomy
05:25

Identification and Protection of the Recurrent Laryngeal Nerve during Transoral Robotic Thyroidectomy

Published on: October 24, 2025

When is prophylactic thyroidectomy indicated for patients with the RET codon 609 mutation?

Daniel Calva1, Thomas M O'Dorisio, M Sue O'Dorisio

  • 1Department of Surgery, Division of Surgical Oncology and Endocrine Surgery, University of Iowa College of Medicine, Iowa City, IA, USA.

Annals of Surgical Oncology
|May 28, 2009
PubMed
Summary

Patients with RET C609Y mutations may delay prophylactic thyroidectomy until ages 10-15. Annual calcitonin screening is recommended before surgery for these MEN2A patients.

More Related Videos

Minimal Invasive Resection of Large Retrosternal Thyroid Goiter
04:09

Minimal Invasive Resection of Large Retrosternal Thyroid Goiter

Published on: September 20, 2024

Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma
04:01

Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma

Published on: September 15, 2023

Related Experiment Videos

Last Updated: Jun 22, 2026

Identification and Protection of the Recurrent Laryngeal Nerve during Transoral Robotic Thyroidectomy
05:25

Identification and Protection of the Recurrent Laryngeal Nerve during Transoral Robotic Thyroidectomy

Published on: October 24, 2025

Minimal Invasive Resection of Large Retrosternal Thyroid Goiter
04:09

Minimal Invasive Resection of Large Retrosternal Thyroid Goiter

Published on: September 20, 2024

Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma
04:01

Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma

Published on: September 15, 2023

Area of Science:

  • Endocrinology
  • Genetics
  • Oncology

Background:

  • Multiple endocrine neoplasia type 2A (MEN2A) is caused by RET proto-oncogene mutations.
  • Prophylactic thyroidectomy is typically recommended before age 5 for MEN2A.
  • The optimal timing for thyroidectomy in patients with RET codon 609 mutations is unclear due to later disease onset.

Purpose of the Study:

  • To evaluate the clinical presentation and optimal timing of thyroidectomy in a family with a RET C609Y mutation.
  • To reassess current recommendations for prophylactic thyroidectomy in MEN2A patients with specific RET mutations.

Main Methods:

  • Analysis of clinical, laboratory, and pathological data from 16 family members who underwent thyroidectomy.
  • Literature review of reported cases involving RET codon 609 mutations.

Main Results:

  • In the studied family, medullary thyroid carcinoma (MTC) was diagnosed in 9/16 patients (mean age 44.7 years), with 6 having lymph node metastases.
  • C-cell hyperplasia (CCH) was observed in two patients at ages 18 and 37.
  • Literature review indicated MTC onset in affected individuals around age 42 and CCH around age 24.

Conclusions:

  • The youngest MTC diagnosis in patients with RET C609Y mutation was 21 years old.
  • The youngest CCH diagnosis was 15 years old.
  • These findings suggest that thyroidectomy can be delayed until ages 10-15 for RET C609Y mutation carriers, with annual calcitonin screening.